- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
LC3 Antibody (APG8A/B)Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP1803a | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
LC3 Antibody (APG8A/B) - Product info | |
| Application | WB, IHC
|
| Primary Accession | Q9GZQ8 |
| Other Accession | A6NCE7, Q62625, Q9CQV6, O41515, Q6XVN8, Q91VR7, Q9H492, Q2HJ23 |
| Reactivity | Human, Mouse, Rat |
| Predicted | Bovine |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 14688 Da |
LC3 Antibody (APG8A/B) - Additional info | |
| Gene ID 81631 | |
| Other Names MAP1LC3B; MAP1ALC3; Microtubule-associated proteins 1A/1B light chain 3B; Autophagy-related protein LC3 B; Autophagy-related ubiquitin-like modifier LC3 B; MAP1 light chain 3-like protein 2; MAP1A/MAP1B light chain 3 B; Microtubule-associated protein 1 light chain 3 beta | |
| Target/Specificity This LC3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 34~64 amino acids surrounding Y38 of human LC3 (APG8a/b). | |
| Dilution WB~~1:50~200WB~~1:1000 IHC~~1:50~100 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions LC3 Antibody (APG8A/B) is for research use only and not for use in diagnostic or therapeutic procedures. | |
LC3 Antibody (APG8A/B) - Protein Information | |
| Name MAP1LC3B | |
| Synonyms MAP1ALC3 | |
| Function Involved in formation of autophagosomal vacuoles (autophagosomes) | |
| Cellular Location Cytoplasm, cytoskeleton. Endomembrane system; Lipid-anchor. Cytoplasmic vesicle, autophagosome membrane; Lipid-anchor. Note=LC3-II binds to the autophagic membranes | |
| Tissue Location Most abundant in heart, brain, skeletal muscle and testis. Little expression observed in liver | |
LC3 Antibody (APG8A/B) - Related products
AP10648a: APG8a/b (MAP1LC3A/B)
AP12484a: APG8b(MAP1LC3B) Antibody (N-term T29)
AP1802a: LC3 Antibody (APG8B) (N-term)
AP1802b: LC3 Antibody (APG8B) (C-term)
AP1802d: LC3 Antibody (APG8B) (T6)
AP1802e: APG8b (MAP1LC3B)-T93/Y99 Antibody (Center)
AP1803a: LC3 Antibody (APG8A/B)
AP1806a: Cleaved LC3B Antibody
AP3530a: Phospho-LC3B-T12 Antibody
AP3713a: Phospho-APG8b (MAP1LC3B)-T6 Antibody
AP3739a: Phospho-APG8b (MAP1LC3B)-T93/Y99 Antibody
AP3744a: Phospho-APG8b (MAP1LC3B)-T29 Antibody
AP3748a: Cleaved-APG8b (MAP1LC3B) Antibody
RI13151: MAP1LC3B predesign siRNA
DC07581: Human MAP1LC3B cDNA Clone
LY12149a: MAP1LC3B Over-expression Lysate
BP10648a: Cleaved-APG8a/b (MAP1LC3A/B) Blocking Peptide
BP1802a: LC3 Antibody (APG8b) (N-term) Blocking Peptide
BP1802b: LC3 Antibody (APG8b) (C-term) Blocking Peptide
BP1802d: APG8b (MAP1LC3B) Antibody (T6) Blocking Peptide
BP1802e: APG8b (MAP1LC3B) Antibody (T93/Y99) Blocking Peptide
BP1803a: LC3 Antibody (APG8a/b) Blocking Peptide
BP1806a: Cleaved-LC3 Antibody (APG8b) Blocking Peptide
BP3530a: Phospho-LC3 (APG8b) - T12 Antibody Blocking Peptide
BP3645a: Phospho-APG8b (MAP1LC3B)-T93 Antibody Blocking Peptide
BP3713a: Phospho-APG8b (MAP1LC3B)-T6 Antibody Blocking Peptide
LC3 Antibody (APG8A/B) - Application data
-
Western blot analysis of anti-Autophagy LC3 Antibody (APG8a/b) (Cat.#AP1803a) in Y79 cell line lysates (35ug/lane). APG8 (arrow) was detected using the purified Pab.
-
Western blot analysis of anti-Autophagy LC3 Antibody (APG8a/b) (Cat.#AP1803a) in mouse lung tissue lysates (35ug/lane). APG8 (arrow) was detected using the purified Pab.
-
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.
LC3 Antibody (APG8A/B) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). MAP1A and MAP1B are microtubule-associated proteins which mediate the physical interactions between microtubules and components of the cytoskeleton. These proteins are involved in formation of autophagosomal vacuoles (autophagosomes). MAP1A and MAP1B each consist of a heavy chain subunit and multiple light chain subunits. MAP1LC3a and MAP1LC3b are light chain subunits and can associate with either MAP1A or MAP1B. The precursor molecules are cleaved by APG4B/ATG4B to form the cytosolic form, LC3-I. This is activated by APG7L/ATG7, transferred to ATG3 and conjugated to phospholipid to form the membrane-bound form, LC3-II.
REFERENCES
Baehrecke EH. Nat Rev Mol Cell Biol. 6(6):505-10. (2005) Lum JJ, et al. Nat Rev Mol Cell Biol. 6(6):439-48. (2005) Greenberg JT. Dev Cell. 8(6):799-801. (2005) Levine B. Cell. 120(2):159-62. (2005) Shintani T and Klionsky DJ. Science. 306(5698):990-5. (2004) Tanida I., et al. Int. J. Biochem. Cell Biol. 36:2503-2518(2004) He H., et al. J. Biol. Chem. 278:29278-29287(2003) Tanida I., et al. J. Biol. Chem. 279:36268-36276(2004)